Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.
Actively Recruiting
This research aims to evaluate the investigational Nevisense Go device for collecting skin measurements from people with atopic dermatitis AD, a condition marked by flare-ups of worsening skin symptoms. The study focuses on participants aged 12 to 89 years who have experienced recent AD flares. It is based on the idea that changes in skin barrier function may happen before visible signs or symptoms of a flare appear. Participants will use the Nevisense Go device at home for about 90 days to measure electrical properties of their skin related to skin barrier function. The study is observational, meaning device measurements will not guide treatment or care. Alongside device use, participants will complete electronic symptom diaries and attend up to five in-person study visits during the study period. During the study, researchers will assess the relationship between skin measurements and AD flares, develop and validate an algorithm using the device data, and evaluate AD severity through patient-reported and clinician-reported outcomes. They will also assess flare resolution, device feasibility, and participant adherence. The total participation lasts approximately 90 days with repeated measurements and study visits throughout this time.
Actively Recruiting
Researchers are evaluating the real-world effectiveness of nemolizumab Nemluvio4 in treating adults with moderate-to-severe Prurigo Nodularis PN. This observational study aims to measure patient and investigator-reported outcomes over approximately 12 months in routine clinical practice. The study focuses on how patients respond to nemolizumab treatment at 6 months, with ongoing assessments up to a year. Participants who have newly started nemolizumab as determined by their physicians will be observed during their usual care visits. No extra visits, procedures, or lab tests beyond routine care are required. A sub-study in Germany and the UK involves daily patient-reported ratings of itch severity and sleep disturbance for two weeks, collected remotely without clinic visits. During the study, participants will undergo routine evaluations by their doctors, including the Investigator Global Assessment of chronic prurigo stage and questionnaires on itch intensity and sleep quality. These assessments occur at 6 months and continue up to 12 months. This approach allows tracking of treatment effects in real-life settings while minimizing additional burden on participants.
Actively Recruiting
Researchers are evaluating the real-world use of nemolizumab for treating moderate-to-severe atopic dermatitis AD in adolescents and adults. This observational study aims to assess the treatments effectiveness through physician evaluations and patient-reported outcomes over six months, providing insight into how the medication performs in everyday clinical practice. Participants receiving nemolizumab as part of their routine care will be observed for about 12 months. Treatment decisions are made by the participants physician before joining the study, with no extra visits or tests beyond usual medical care. A sub-study in Germany and the UK involves daily remote reporting of symptoms such as peak and average itch, sleep disturbance, and pain for the first two weeks. During the study, participants will have regular medical visits as determined by their doctors, with data collected from routine assessments and patient questionnaires. Researchers will measure outcomes like the Investigator Global Assessment and Peak Pruritus Numerical Rating Scale at six months, along with other severity and symptom scores up to 12 months. No additional procedures outside standard care are required, allowing for natural monitoring of treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called ICP-332 in adults with Prurigo Nodularis PN, a skin condition characterized by itchy nodules. This study is a Phase 2 clinical trial designed to compare different doses of ICP-332 against a placebo to better understand its potential benefits and risks for people with PN. Participants are randomly assigned to receive either ICP-332 at doses of 80 mg or 120 mg, or a placebo, with neither the participants nor the researchers knowing which treatment is given to ensure unbiased results. The study involves a 16-week treatment period to assess itch severity, followed by continued assessments up to 40 weeks to monitor skin condition improvements, quality of life, and any side effects. Blood tests will measure how the drug is processed by the body. Throughout the study, participants will be monitored regularly with evaluations of their itch intensity using a numeric scale, skin assessments by doctors, and quality of life questionnaires. Safety will be closely tracked by recording any adverse events. Participants involvement may last up to 40 weeks, including treatment and follow-up periods to gather comprehensive information about ICP-332s impact on Prurigo Nodularis.
Actively Recruiting
Researchers are studying atopic dermatitis AD in adolescents and adults to better understand the unmet needs across this condition and to observe how systemic treatments work in real-world settings. This observational study aims to explore patients journeys, including factors like age, skin color, flare triggers, past treatment responses, comorbidities, and lesion characteristics. It involves multiple countries and diverse populations to capture a broad picture of treatment impacts over time. The study follows patients who begin or switch any systemic treatment for AD, such as biologics, oral Janus kinase inhibitors, cyclosporine, azathioprine, methotrexate, or mycophenolate mofetil, as prescribed by their doctors based on local guidelines. Researchers do not assign treatments but collect information on treatment choices and changes during standard care. This registry will track treatment sequences, interruptions, dose changes, and reasons for starting or stopping treatments over a five-year period. Participants will be followed for up to five years to monitor their treatment experience and disease progression. Data collection includes assessments of disease severity using tools like the Eczema Area and Severity Index EASI, body surface area affected, and global assessments of AD. Patient-reported outcomes such as itch, skin pain, sleep disturbance, quality of life, work productivity, and treatment satisfaction will also be recorded. Safety will be monitored through reports of adverse events. The study collects demographics, comorbid conditions, healthcare visits, and medication use to provide a comprehensive view of AD management in everyday care.